Clinical experience with denosumab discontinuation
Osteoporosis International · 2025-03 · 36 (3) · 435-446
DOI: 10.1007/s00198-024-07351-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Osteoporosis International, online erschienen am 08.01.2025. Verfasst von Natasha Laursen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark. natalu@rm.dk. Hauptthemen laut MEDLINE: Denosumab, Bone Density Conservation Agents, Osteoporosis. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark. natalu@rm.dk.
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. natalu@rm.dk.
- Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Zitieren
APA
Laursen, N., Sølling, A. S., Harsløf, T., & Langdahl, B. (2025). Clinical experience with denosumab discontinuation. Osteoporosis International, 36(3), 435-446. https://doi.org/10.1007/s00198-024-07351-7
Vancouver
Laursen N, Sølling AS, Harsløf T, Langdahl B. Clinical experience with denosumab discontinuation. Osteoporosis International. 2025;36(3):435-446. doi:10.1007/s00198-024-07351-7
BibTeX
@article{Laursen2025,
author = {Laursen, Natasha and Sølling, Anne Sophie and Harsløf, Torben and Langdahl, Bente},
title = {Clinical experience with denosumab discontinuation},
journal = {Osteoporosis International},
year = {2025},
volume = {36},
number = {3},
pages = {435--446},
doi = {10.1007/s00198-024-07351-7}
}
EUVIMED